3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
69
Carcinoma, Non-Small-Cell Lung
41
Carcinoma, Renal Cell
38
Neoplasm Metastasis
22
Carcinoma, Hepatocellular
15
Neoplasms
14
Colorectal Neoplasms
13
Brain Neoplasms
13
Skin Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
11
Pancreatic Neoplasms
10
Lung Neoplasms
10
Kidney Neoplasms
10
Uveal Melanoma
9
Ovarian Neoplasms
9
Urinary Bladder Neoplasms
8
Sarcoma
8
Prostatic Neoplasms
8
Carcinoma, Transitional Cell
8
Mesothelioma
7
Glioblastoma
7
Clear-cell metastatic renal cell carcinoma
7
Carcinoma, Merkel Cell
7
Recurrence
6
Myelodysplastic Syndromes
6
Colonic Neoplasms
6
Triple Negative Breast Neoplasms
5
Small Cell Lung Carcinoma
5
Multiple Myeloma
5
Mesothelioma, Malignant
5
Interventions
Gemcitabine
5
Taxes
3
Albumin-Bound Paclitaxel
3
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Oxaliplatin
2
Losartan
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
130-nm albumin-bound paclitaxel
2
tocilizumab
1
selicrelumab
1
niraparib
1
durvalumab
1
dehydroftorafur
1
cobimetinib
1
atezolizumab
1
X-Rays
1
Tiragolumab
1
Standard of Care
1
Specimen Handling
1
Radiation
1
Panitumumab
1
Pancreaticoduodenectomy
1
PEGPH20
1
Optical Imaging
1
Nivolumab
1
Metformin
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Adenocarcinoma
×
Ipilimumab
×
1 year
×
Clear all
NCT03404960
2025-10-10
Parpvax
University of Pennsylvania
Phase 1/2
Completed
104 enrolled
11 charts